Seattle firm aims to develop self-driving hospital to go to patients

Cara Livernois | | Health Exec | Economics

Artefact, a Seattle-based design firm, is bringing the hospital to patients with what it calls a hospital in a self-driving car. "Aim" aims to bring healthcare into the future with all the amenities of a hospital without the need to travel.

Aim, with artificial intelligence-enabled home technologies to track vital signs, is able to monitor a user's health and call a self-driving hospital when needed. The hospital car is able to travel directly to patient at home or work. Aim can take measurements including weight, blood pressure, body mass index and heart rate. A screen provides also allows for patients to receive care instructions. Aim also comes with a built-in pharmacy, using artificial intelligence to fill prescriptions on the spot.

“Aim is about creating an environment or a system where more positive health outcomes can occur—More engagement with patients, technology with clinicians, and transparency from a standpoint of economic value.”

Read the full story below:

Who Needs A Hospital, When This Self-Driving Doctor Comes To You?

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.